Risks and Liquidity (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Unusual Risk or Uncertainty [Line Items]
Accumulated deficit	$ (349,522)		$ (320,889)
Proceeds from the sale of product line	5,366
Received net proceeds of after deducting underwriting discounts, commissions and other offering expenses		$ 46,341
MiMedx Group, Inc.
Unusual Risk or Uncertainty [Line Items]
Proceeds from the sale of product line	$ 5,000
Period of net sales considered for calculating additional future payment receivable	2 years
MiMedx Group, Inc. | Maximum [Member]
Unusual Risk or Uncertainty [Line Items]
Revenue sharing payments	$ 7,000
MiMedx Group, Inc. | Minimum [Member]
Unusual Risk or Uncertainty [Line Items]
Revenue sharing payments	$ 3,000